Single flu and covid vaccine test has promising result

Tests in animal models showed antibody production induced by the immunizer against the three strains of influenza and against the new coronavirus. (Credit: Playback/Pixabay)

The Butantan Institute reported last week that it obtained promising results in preliminary tests of the single vaccine against influenza and covid-19. According to the São Paulo agency, tests in animal models showed production of antibodies induced by the immunizer against the three strains of influenza (H1N1, H3N2 and B) and against the new coronavirus.

+ Omicron or Influenza? See which virus is the deadliest

Butantan believes that clinical trials in humans can be started within a year. This step is crucial to verify the safety and effectiveness of the product.

According to the institute, the project for a new vaccine, conducted by Brazilian scientists in partnership with international bodies, has the potential to make it cheaper and increase the production capacity of vaccines for Brazil and other developing countries.

The American laboratory Novavax is also looking for a unique immunizer. Human trials began in September in Australia, after promising results from pre-clinical trials, according to the drugmaker. The expectation is to release data from the new testing phase this semester. Moderna, also an American company, is another one that has already announced plans to launch a single vaccine in 2023.